Share

April 10, 2018; 90 (15 Supplement) April 25, 2018

Non-myeloablative hematopoietic stem cell transplantation (HSCT) is superior to disease modifying drug (DMD) treatment in highly active Relapsing Remitting Multiple Sclerosis (RRMS): interim results of the Multiple Sclerosis International Stem cell Transplant (MIST) Randomized Trial (S36.004)

Richard K. Burt, Roumen Balabanov, John A. Snowden, Basil Sharrack, Maria Carolina Oliveira, Joachim Burman
First published April 9, 2018,
Citation
Permissions

Make Comment

See Comments

Downloads
0

Share

Article Information

vol. 90 no. 15 Supplement S36.004
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • First Published April 9, 2018.
Copyright & Usage: 
© 2018

Author Disclosures

    1. Richard K. Burt1,
    2. Roumen Balabanov2,
    3. John A. Snowden3,
    4. Basil Sharrack4,
    5. Maria Carolina Oliveira5 and
    6. Joachim Burman6
  1. Richard K. Burt1,
  2. Roumen Balabanov2,
  3. John A. Snowden3,
  4. Basil Sharrack4,
  5. Maria Carolina Oliveira5 and
  6. Joachim Burman6
  1. 1Division of Immunotherapy, Northwestern University Chicago IL United States
  2. 2Department of Neurology, Northwestern University Chicago IL United States
  3. 3Department of Haematology, Sheffield Teaching Hospitals Sheffield United Kingdom
  4. 4Department of Neurology, Sheffield Teaching Hospitals Sheffield United Kingdom
  5. 5University of Sao Paulo Sao Paulo Brazil
  6. 6Department of Neuroscience, Uppsala University Hudiksvall Sweden

Article usage

Article usage: April 2018 to October 2023

AbstractFullPdfSource
Apr 201832100Highwire
May 201845100Highwire
Jun 201828700Highwire
Jul 2018194100Highwire
Aug 2018656200Highwire
Sep 201855400Highwire
Oct 201851300Highwire
Nov 201828900Highwire
Dec 201820800Highwire
Jan 201922300Highwire
Feb 201916600Highwire
Mar 201920000Highwire
Apr 201920900Highwire
May 201910300Highwire
Jun 20198300Highwire
Jul 201915800Highwire
Aug 201913100Highwire
Sep 201925100Highwire
Oct 201921100Highwire
Nov 201912800Highwire
Dec 201911100Highwire
Jan 202012700Highwire
Feb 202056000Highwire
Mar 202014400Highwire
Apr 20207100Highwire
May 202014100Highwire
Jun 202010300Highwire
Jul 20207600Highwire
Aug 20204700Highwire
Sep 20206600Highwire
Oct 20206300Highwire
Nov 202010300Highwire
Dec 202014900Highwire
Jan 202111700Highwire
Feb 20217000Highwire
Mar 202110600Highwire
Apr 20219700Highwire
May 20217700Highwire
Jun 20214200Highwire
Jul 20213300Highwire
Aug 20215900Highwire
Sep 20219400Highwire
Oct 20215900Highwire
Nov 20216100Highwire
Dec 20218300Highwire
Jan 20228100Highwire
Feb 20227800Highwire
Mar 20227100Highwire
Apr 20228300Highwire
May 20226600Highwire
Jun 20224500Highwire
Jul 20225400Highwire
Aug 20224600Highwire
Sep 20225600Highwire
Oct 20224600Highwire
Nov 20228200Highwire
Dec 20223100Highwire
Jan 20235000Highwire
Feb 20232800Highwire
Mar 20234000Highwire
Apr 20233500Highwire
May 20234800Highwire
Jun 20234600Highwire
Jul 20235000Highwire
Aug 20234200Highwire
Sep 20233800Highwire
Oct 20233300Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. [email protected]
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Alert Me